ERBB2 and neoplasm: The HER2-DC1 i.t. combined with anti-HER2 antibodies treatment group had a higher number of tumor infiltrating CD4+ T cells, compared with the HER2-DC1 s.c. combined with anti-HER2 antibodies treatment group (figure 3A).